{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T13:17:48Z","timestamp":1772025468413,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The existing treatments for somatoform dysfunction (SfD), reaction to severe stress (RSS), and adjustment disorders (AjD) are insufficiently effective and safe. Anxiolytic drug Tenoten proved effective in clinical trials (CT). The aim of this multicenter double-blind placebo-controlled randomized CT was to investigate the safety and efficacy of Tenoten in the treatment of anxiety in adults with SfD, RSS, AjD and other neurotic disorders (oNDs). 390 adult patients with SfD, RSS and AjD or oNDs with the Hospital Anxiety and Depression scale-anxiety (HADS-A) score\u2009\u2265\u200911 were randomized into 4 groups (n\u2009=\u2009127 in Tenoten group 1 (4 tablets\/day); n\u2009=\u2009131 in Tenoten group 3 (8 tablets\/day), n\u2009=\u2009132 in combined Placebo group 2\u2009+\u20094). The changes from baseline in the mean Hamilton Anxiety Rating Scale (HAM-A) score in groups 1 and 3 after 12\u00a0weeks were the primary outcome. The decrease of the HAM-A score from 18.81\u2009\u00b1\u20095.81 to 7.26\u2009\u00b1\u20094.63 (in group 1) and from 18.38\u2009\u00b1\u20094.3 to 6.40\u2009\u00b1\u20094.02 (in group 3) was observed post-treatment (p<jats:sub>group 1\/placebo<\/jats:sub>\u2009=\u20090.0055, p<jats:sub>group 3\/placebo<\/jats:sub>\u2009&lt;\u20090.0001). Overall, 46 adverse events (28 in the Tenoten groups and 18 in the Placebo) were reported without any difference between the study groups. Tenoten performed significantly more effective than placebo in the anxiety treatment of adults with SfD, RSS, AjD and oNDs (clinicaltrials.gov NCT03036293).<\/jats:p>","DOI":"10.1038\/s41598-021-03727-5","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T11:13:41Z","timestamp":1639998821000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["RETRACTED ARTICLE: The randomized clinical trial results of the anxiety treatment in patients with somatoform dysfunction and neurotic disorders"],"prefix":"10.1038","volume":"11","author":[{"given":"Vladimir Anatolevich","family":"Parfenov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel Rudolfovich","family":"Kamchatnov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina Rustemovna","family":"Khasanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enver Ibragimovich","family":"Bogdanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana Markovna","family":"Lokshtanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandr Vitalevich","family":"Amelin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalya Nikolaevna","family":"Maslova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nataliia Vyacheslavovna","family":"Pizova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galina Nikolaevna","family":"Belskaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evgeny Robertovich","family":"Barantsevich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulsum Abdurahmanovna","family":"Duchshanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saltanat Ualihanovna","family":"Kamenova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oleg Vladimirovich","family":"Kolokolov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexey Borisovich","family":"Glazunov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,20]]},"reference":[{"issue":"9","key":"3727_CR1","doi-asserted-by":"publisher","first-page":"e0138342","DOI":"10.1371\/journal.pone.0138342","volume":"10","author":"A Weiland","year":"2015","unstructured":"Weiland, A. et al. Training medical specialists to communicate better with patients with medically unexplained physical symptoms (MUPS): A randomized, controlled trial. PLoS ONE10(9), e0138342. https:\/\/doi.org\/10.1371\/journal.pone.0138342 (2015).","journal-title":"PLoS ONE"},{"issue":"16","key":"3727_CR2","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3238\/arztebl.2015.0279","volume":"112","author":"H Haller","year":"2015","unstructured":"Haller, H., Cramer, H., Lauche, R. & Dobos, G. Somatoform disorders and medically unexplained symptoms in primary care. Dtsch Arztebl Int.112(16), 279\u2013287. https:\/\/doi.org\/10.3238\/arztebl.2015.0279 (2015).","journal-title":"Dtsch Arztebl Int."},{"issue":"1","key":"3727_CR3","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1186\/s12888-018-1940-3","volume":"18","author":"K Piontek","year":"2018","unstructured":"Piontek, K., Shedden-Mora, M. C., Gladigau, M., Kuby, A. & L\u00f6we, B. Diagnosis of somatoform disorders in primary care: Diagnostic agreement, predictors, and comaprisons with depression and anxiety. BMC Psychiatry18(1), 361. https:\/\/doi.org\/10.1186\/s12888-018-1940-3 (2018).","journal-title":"BMC Psychiatry"},{"issue":"3","key":"3727_CR4","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S2215-0366(19)30031-8","volume":"6","author":"SJ Lewis","year":"2019","unstructured":"Lewis, S. J. et al. The epidemiology of trauma and post-traumatic stress disorder in a representative cohort of young people in England and Wales. Lancet Psychiatry6(3), 247\u2013256. https:\/\/doi.org\/10.1016\/S2215-0366(19)30031-8 (2019).","journal-title":"Lancet Psychiatry"},{"issue":"36","key":"3727_CR5","doi-asserted-by":"publisher","first-page":"e7994","DOI":"10.1097\/MD.0000000000007994","volume":"96","author":"W Dai","year":"2017","unstructured":"Dai, W. et al. Comorbidity of post-traumatic stress disorder and anxiety in flood survivors: prevalence and shared risk factors. Medicine96(36), e7994. https:\/\/doi.org\/10.1097\/MD.0000000000007994 (2017).","journal-title":"Medicine"},{"issue":"1","key":"3727_CR6","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12913-016-1332-7","volume":"16","author":"M den Boeft","year":"2016","unstructured":"den Boeft, M. et al. The association between medically unexplained physical symptoms and health care use over two years and the influence of depressive and anxiety disorders and personality traits: A longitudinal study. BMC Health Serv. Res.16(1), 100. https:\/\/doi.org\/10.1186\/s12913-016-1332-7 (2016).","journal-title":"BMC Health Serv. Res."},{"issue":"2","key":"3727_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.4088\/pcc.v02n0204","volume":"2","author":"AJ Gelenberg","year":"2000","unstructured":"Gelenberg, A. J. Psychiatric and somatic markers of anxiety: identification and pharmacologic treatment. J. Clin. Psychiatry.2(2), 49. https:\/\/doi.org\/10.4088\/pcc.v02n0204 (2000).","journal-title":"J. Clin. Psychiatry."},{"key":"3727_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0301-0511(00)00042-9","volume":"53","author":"W Rief","year":"2000","unstructured":"Rief, W. & Auer, C. Cortisol and somatization. Biol. Psychol.53, 13\u201323. https:\/\/doi.org\/10.1016\/S0301-0511(00)00042-9 (2000).","journal-title":"Biol. Psychol."},{"key":"3727_CR9","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.bbi.2007.04.008","volume":"21","author":"JH Houtveen","year":"2007","unstructured":"Houtveen, J. H., Kavelaars, A., Heijnen, C. J. & van Doornen, L. J. Heterogeneous medically unexplained symptoms and immune function. Brain Behav. Immun.21, 1075\u20131082. https:\/\/doi.org\/10.1016\/j.bbi.2007.04.008 (2007).","journal-title":"Brain Behav. Immun."},{"issue":"6","key":"3727_CR10","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1192\/bjp.184.6.470","volume":"184","author":"MWM De Waal","year":"2004","unstructured":"De Waal, M. W. M., Arnold, I. A., Eekhof, J. A. & Van Hemert, A. M. Somatoform disorders in general practice: Prevalence, functional impairment and comorbidity with anxiety and depressive disorders. Br. J. Psychiatry184(6), 470\u2013476. https:\/\/doi.org\/10.1192\/bjp.184.6.470 (2004).","journal-title":"Br. J. Psychiatry"},{"issue":"11","key":"3727_CR11","doi-asserted-by":"publisher","first-page":"010628","DOI":"10.1002\/14651858.CD010628.pub2","volume":"7","author":"M Kleinstaeuber","year":"2014","unstructured":"Kleinstaeuber, M. et al. Pharmacological interventions for somatoform disorders in adults. Cochrane Library.7(11), 010628. https:\/\/doi.org\/10.1002\/14651858.CD010628.pub2 (2014).","journal-title":"Cochrane Library."},{"key":"3727_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011142","author":"N Van Dessel","year":"2014","unstructured":"Van Dessel, N. et al. Non-pharmacological interventions forsomatoform disorders and medically unexplained physical symptoms (MUPS) in adults. Cochrane Library.https:\/\/doi.org\/10.1002\/14651858.CD011142 (2014).","journal-title":"Cochrane Library."},{"issue":"10","key":"3727_CR13","first-page":"499","volume":"31","author":"D Wedekind","year":"2005","unstructured":"Wedekind, D. & Bandelow, B. Trends in the treatment of anxiety disorders. Dialog. Clin. Neurosci.31(10), 499\u2013503 (2005).","journal-title":"Dialog. Clin. Neurosci."},{"issue":"2","key":"3727_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1192\/bjp.bp.114.148551","volume":"206","author":"M Hoskins","year":"2015","unstructured":"Hoskins, M. et al. Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis. Br. J. Psychiatry206(2), 93\u2013100. https:\/\/doi.org\/10.1192\/bjp.bp.114.148551 (2015).","journal-title":"Br. J. Psychiatry"},{"issue":"4","key":"3727_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3390\/sym10040103","volume":"10","author":"O Epstein","year":"2018","unstructured":"Epstein, O. The spatial homeostasis hypothesis. Symmetry.10(4), 103. https:\/\/doi.org\/10.3390\/sym10040103 (2018).","journal-title":"Symmetry."},{"issue":"5","key":"3727_CR16","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.4049\/jimmunol.2000098","volume":"205","author":"SA Tarasov","year":"2020","unstructured":"Tarasov, S. A. et al. Insights into the mechanism of action of highly diluted biologics. J. Immunol.205(5), 1345\u20131354. https:\/\/doi.org\/10.4049\/jimmunol.2000098 (2020).","journal-title":"J. Immunol."},{"key":"3727_CR17","doi-asserted-by":"publisher","first-page":"a79","DOI":"10.2741\/1025","volume":"8","author":"OI Epstein","year":"2003","unstructured":"Epstein, O. I. et al. Membrane and synaptic effects of anti-S-100 are prevented by the same antibodies in low concentrations. Front Biosci.8, a79-84. https:\/\/doi.org\/10.2741\/1025 (2003).","journal-title":"Front Biosci."},{"issue":"Suppl 7","key":"3727_CR18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1023\/a:1024776007215","volume":"135","author":"TA Voronina","year":"2003","unstructured":"Voronina, T. A., Molodavkin, G. M., Sergeeva, S. A. & Epstein, O. I. GABAergic system in the anxiolytic effect of Proproten: Experimental study. Bull. Exp. Biol. Med.135(Suppl 7), 125\u2013127. https:\/\/doi.org\/10.1023\/a:1024776007215 (2003).","journal-title":"Bull. Exp. Biol. Med."},{"issue":"5","key":"3727_CR19","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1007\/s10517-007-0191-y","volume":"143","author":"IA Kheifets","year":"2007","unstructured":"Kheifets, I. A. et al. Involvement of the serotoninergic system in the mechanism of action of ultralow dose antibodies to S-100 protein. Bull. Exp. Biol. Med.143(5), 598\u2013600. https:\/\/doi.org\/10.1007\/s10517-007-0191-y (2007).","journal-title":"Bull. Exp. Biol. Med."},{"key":"3727_CR20","unstructured":"Ertuzun, I. A. Mekhanizmy anksioliticheskogo i antidepressatnogo dejstviya Tenotena (eksperimental'noe issledovanie). Avtoreferat Dissertacii na Soiskanie Uchenoj Stepeni Kandidata Medicinskih Nauk. (2012) [in Russian]."},{"key":"3727_CR21","first-page":"48","volume":"1","author":"LI Larentsova","year":"2008","unstructured":"Larentsova, L. I. et al. Eksperimental\u2019no-klinicheskoe izuchenie tenotena (antitela k mozgospecificheskomu belku S-100) i vozmozhnosti ego primeneniya v kachestve sredstva premedikacii na ambulatornom stomatologicheskom prieme. Rossijskaya Stomatol.1, 48\u201351 (2008) (in Russian).","journal-title":"Rossijskaya Stomatol."},{"issue":"3","key":"3727_CR22","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1007\/s10517-010-0756-z","volume":"148","author":"TA Voronina","year":"2009","unstructured":"Voronina, T. A., Kheyfets, I. A., Dugina, Y. L., Sergeeva, S. A. & Epshtein, O. I. Study of the effects of preparation containing ultralow doses of antibodies to S-100 protein in experimental hemorrhagic stroke. Bull. Exp. Biol. Med.148(3), 530\u2013532. https:\/\/doi.org\/10.1007\/s10517-010-0756-z (2009).","journal-title":"Bull. Exp. Biol. Med."},{"issue":"3","key":"3727_CR23","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s10517-010-0754-1","volume":"148","author":"TA Voronina","year":"2009","unstructured":"Voronina, T. A. et al. Nootropic and antiamnestic effects of tenoten (pediatric formulation) in immature rat pups. Bull. Exp. Biol. Med.148(3), 524\u2013526. https:\/\/doi.org\/10.1007\/s10517-010-0754-1 (2009).","journal-title":"Bull. Exp. Biol. Med."},{"key":"3727_CR24","first-page":"52","volume":"137","author":"TA Voronina","year":"2006","unstructured":"Voronina, T. A., Sergeeva, S. A., Martyushev-Poklad, A. V., Dugina, J. L. & Epstein, O. I. Antibodies to S-100 protein in anxiety-depressive disorders in experimental and clinical conditions. Anim. Model Biol. Psychiatry137, 52 (2006).","journal-title":"Anim. Model Biol. Psychiatry"},{"issue":"3","key":"3727_CR25","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1007\/s10517-011-1324-x","volume":"151","author":"IA Kheyfets","year":"2011","unstructured":"Kheyfets, I. A., Voronina, T. A., Dugina, J. L., Molodavkin, G. M. & Sergeeva, S. A. Anxiolytic activity of tenoten and diazepam depends on conditions in Vogel conflict test. Bull. Exp. Biol. Med.151(3), 336\u2013339. https:\/\/doi.org\/10.1007\/s10517-011-1324-x (2011).","journal-title":"Bull. Exp. Biol. Med."},{"issue":"1","key":"3727_CR26","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s10517-010-0757-y","volume":"148","author":"TA Voronina","year":"2009","unstructured":"Voronina, T. A. et al. Effect of ultralow doses of antibodies to S-100 protein in animals with impaired cognitive function and disturbed emotional and neurological status under conditions of experimental Alzheimer disease. Bull. Exp. Biol. Med.148(1), 533\u2013535. https:\/\/doi.org\/10.1007\/s10517-010-0757-y (2009).","journal-title":"Bull. Exp. Biol. Med."},{"key":"3727_CR27","first-page":"120","volume":"1","author":"TA Voronina","year":"2003","unstructured":"Voronina, T. A., Molodavkin, G. M., Sergeeva, S. A. & Epstein, O. I. Anxiolytic effect of proproten under conditions of punished and unpunished behavior. Bull. Exp. Biol. Med.1, 120\u2013122 (2003).","journal-title":"Bull. Exp. Biol. Med."},{"key":"3727_CR28","unstructured":"Official site of the Ministry of Health of the Russian Federation, registered drugs and clinical trials information. https:\/\/grls.rosminzdrav.ru\/Grls_View_v2.aspx?routingGuid=022e51ba-4296-433b-8293-4f7c1cc9b02e&t."},{"key":"3727_CR29","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ijid.2019.09.028","volume":"89","author":"E Andrianova","year":"2019","unstructured":"Andrianova, E. & Putilovskiy, M. Efficacy and safety of Ergoferon versus oseltamivir: reply to the Letter to the Editor. Int. J. Infect. Dis.89, 190\u2013192. https:\/\/doi.org\/10.1016\/j.ijid.2019.09.028 (2019).","journal-title":"Int. J. Infect. Dis."},{"key":"3727_CR30","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.92207","author":"KK Khacheva","year":"2020","unstructured":"Khacheva, K. K., Khakimova, G. R., Glazunov, A. B. & Fateeva, V. V. Technologically processed highly diluted antibodies to S100 protein in the treatment of neurotic disorders: The review. Anxiety Disord.https:\/\/doi.org\/10.5772\/intechopen.92207 (2020).","journal-title":"Anxiety Disord."},{"issue":"2","key":"3727_CR31","doi-asserted-by":"publisher","first-page":"93","DOI":"10.31887\/DCNS.2017.19.2\/bbandelow","volume":"19","author":"B Bandelow","year":"2017","unstructured":"Bandelow, B., Michaelis, S. & Wedekind, D. Treatment of anxiety disorders. Dialog. Clin. Neurosci.19(2), 93 (2017).","journal-title":"Dialog. Clin. Neurosci."},{"issue":"12","key":"3727_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-012379","volume":"6","author":"AKW Brownell","year":"2016","unstructured":"Brownell, A. K. W., Atkins, C., Whiteley, A., Woollard, R. F. & Kornelsen, J. Clinical practitioners\u2019 views on the management of patients with medically unexplained physical symptoms (MUPS): a qualitative study. BMJ Open6(12), e012379. https:\/\/doi.org\/10.1136\/bmjopen-2016-012379 (2016).","journal-title":"BMJ Open"},{"issue":"9","key":"3727_CR33","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/nrd4075","volume":"12","author":"G Griebel","year":"2013","unstructured":"Griebel, G. & Holmes, A. 50 years of hurdles and hope in anxiolytic drug discovery. Nat. Rev. Drug Discov.12(9), 667\u2013687. https:\/\/doi.org\/10.1038\/nrd4075 (2013).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3727_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.24411\/2071-5315-2019-12153","volume":"4","author":"KK Khacheva","year":"2019","unstructured":"Khacheva, K. K., Glazunov, A. B. & Kamchatnov, P. R. The efficacy and safety of the most prescribed drugs with anxiolytic effect in the Russian Federation. Lechebnoye Delo.4, 15\u201327. https:\/\/doi.org\/10.24411\/2071-5315-2019-12153 (2019).","journal-title":"Lechebnoye Delo."}],"updated-by":[{"DOI":"10.1038\/s41598-022-19938-3","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"record-id":"39070"},{"DOI":"10.1038\/s41598-022-19938-3","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03727-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03727-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03727-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T18:20:53Z","timestamp":1670091653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03727-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,20]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["3727"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-03727-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,20]]},"assertion":[{"value":"2 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been retracted. Please see the Retraction Notice for more detail:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-022-19938-3","URL":"https:\/\/doi.org\/10.1038\/s41598-022-19938-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors received an investigator grant from OOO NPF Materia Medica Holding to conduct the CT of Tenoten mentioned in this article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24282"}}